

PRESCRIBING INFORMATION

OVIXAN® 1 mg/g cream (mometasone furoate) PRESCRIBING INFORMATION

Please consult the Summary of Product Characteristics (SmPC) before prescribing

Presentation: Each g of cream contains 1 mg mometasone furoate (0.1% w/w). Excipients with known effect: propylene glycol (E1520) and cetostearyl alcohol. See SmPC for full list. **Indication:** Treatment of inflammatory and pruritic manifestations of psoriasis (excluding widespread plaque psoriasis) and atopic dermatitis. **Dose and administration:** *Adults including elderly and Children:* Apply a thin film to the affected areas of skin once daily. Use in children or on the face should be limited to the least amount compatible with an effective therapeutic regimen and duration of treatment should be no more than 5 days. **Contraindications:** Hypersensitivity to active substance mometasone furoate, to other corticosteroids, or to any excipients. Facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal and genital pruritus, napkin eruptions, bacterial (e.g. impetigo, pyoderma), viral (e.g. herpes simplex, herpes zoster and chickenpox verrucae vulgares, condylomata acuminata, molluscum contagiosum), parasitological and fungal (e.g. candida or dermatophyte) infections, varicella, tuberculosis, syphilis or post-vaccine reactions. Should not be used on wounds or on skin which is ulcerated. **Special warnings and precautions:** Strong steroid. Discontinue if irritation or sensitization develop. If an infection develops, use the appropriate antifungal or antibacterial agent. If no prompt improvement occurs, discontinue the corticosteroid until the infection is controlled. Systemic absorption of topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria, especially in children. Not recommended for children under 2 years old. Patients using corticosteroids on large areas or under occlusion should be monitored for HPA axis suppression. Long-term use, especially on large or damaged areas, can lead to local and systemic toxicity. Avoid occlusion when treating children or the face; and limit use to 5 days. Avoid sudden withdrawal after long-term use to prevent rebound dermatitis. Do not use around the eyes due to the risk of glaucoma or cataracts. Fabrics in contact with the product may present a fire hazard. Long-term use can lead to withdrawal symptoms, such as intense redness and burning, particularly in delicate areas like the face. If symptoms return after treatment, consider withdrawal reactions and seek specialist advice. See SmPC for further details. **Pregnancy and lactation:** Use during pregnancy and lactation only if the potential benefit justifies the potential risk. Animal studies show topical corticosteroids can cause foetal abnormalities. Although human risk is unknown, foetal growth effects cannot be ruled out. Avoid prolonged use and large area application during pregnancy. Discontinue breastfeeding if high doses or long-term treatment are required. **Undesirable effects:** *Very rare (<1/10 000):* folliculitis, burning sensation, pruritus. *Frequency not known:* infection, furuncle, paraesthesia, dermatitis contact, skin hypopigmentation, hypertrichosis, skin striae, dermatitis acneiform, skin atrophy, withdrawal reactions (redness of the skin which may extend to areas beyond the initial affected area, burning or stinging sensation, itch, skin peeling, oozing pustules), application site pain, application site reactions, vision blurred. See SmPC for a full list of undesirable effects. **Legal Category:** POM. **Basic UK NHS cost:** £4.40/£14.10 per 30g/100g tube. **Market authorization (MA) number:** PLGB 34942/0004. **MA holder:** Biofrontera Bioscience GmbH, Hemmelrather Weg 201, 51377 Leverkusen, Germany. **Date of preparation of PI:** Nov 2025.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Biofrontera Pharma GmbH on +49 214 876 32 66



Biofrontera 
Deep in dermatology



**HYDROPHILIC
BY DESIGN
TO ENHANCE
PATIENT
EXPERIENCE**

Available in
30g and **100g**

NEW

Ovixan® MOMETASONE CREAM REFORMULATED

Ovixan® cream is indicated for the treatment of inflammatory and pruritic manifestations of Psoriasis (excluding widespread Plaque Psoriasis) and Atopic Dermatitis.

Ovixan® is a potent topical corticosteroid. Consult the SmPC before prescribing.

WHY CHOOSE **Ovixan**®?

Mometasone furoate is a well-established topical corticosteroid frequently used in inflammatory skin conditions because it offers a balanced efficacy and safety profile.¹

Positive patient experience is an important consideration when it comes to treatment completion and a successful outcome for both patient and healthcare professional.

Studies suggest that up to

70%

of patients do not adhere to their topical Psoriasis treatment.^{2,3}

APPLICATION

Patients should be directed to apply a thin layer of Ovixan® once daily to the affected areas of skin.⁸



THIS IS WHY WE CREATED **Ovixan**®

Featuring an oil-in-water formulation for a hydrophilic cream⁴, Ovixan® is not only considered to be “therapeutically equivalent” to alternative lipophilic mometasone cream, Elocon®*⁵, but is also designed with the patient experience in mind.

*Elocon® is a registered trademark of N.V. ORGANON.

THE SCIENCE BEHIND **Ovixan®**

The hydrophilic nature of Ovixan® provides an alternative to the commonly used lipophilic mometasone creams, such as Elocon®*.

Reformulated: Ingredients picked for purpose

White soft paraffin →
Coconut oil

White soft paraffin has been replaced with coconut oil, designed to aid in the production of a smooth, non-grainy texture.⁶

Titanium dioxide →
Coconut oil

Coconut oil forms a naturally white emulsion,⁶ negating the need for titanium dioxide. Ovixan® absorbs without visible residue.⁷

Lipophilic →
Hydrophilic

Our oil-in-water formulation means the 50% water concentration is designed to be easily applied and to absorb into the skin.⁴

Illustration purposes only



Oil in Water Formulation

Illustration purposes only



Water in Oil Formulation

Ovixan®

~50%

Water
Concentration⁴

~3%

Water
Concentration⁴

Elocon®

SAFETY INFORMATION

The latest guidance on topical corticosteroids states that the lowest effective potency should be prescribed using an appropriate duration, formulation and quantity.⁹

Consult the Ovixan® SmPC before prescribing.

- Ovixan® is a potent corticosteroid.⁸
- Use of Ovixan® in children or on the face should be limited to the least amount possible, for no more than 5 days.⁸
- Ovixan® is licensed for use in adults and children aged 2+.⁸
- Do not use Ovixan® around the eyes or in children under 2 years of age.

Long-term use can lead to local and systemic toxicity and withdrawal symptoms. Long-term continuous therapy should be avoided.

COULD Ovixan® BE YOUR MOMETASONE TREATMENT OF CHOICE?

Once Daily Efficacy

- Considered **“therapeutically equivalent”** to Elocon® cream.*⁵
- **Designed** to support patient adherence.
- **Simple** dosing.

Reformulated for Patient Experience

- **Odourless.**⁸
- **Easily absorbed** into the skin, leaving no visible residue after application.⁷
- **Designed** with a smooth, non-grainy texture to promote even application.⁷

A Reliable Option for HCPs and Payors

- **Robust** supply chain.
- Shelf life of up to **three years**.
- **Competitively** priced.

References: **1.** Molin S, Abeck D, Guilabert A, et al. J Clin Exp Dermatol Res. 2013;4(3). **2.** Teixeira A, Teixeira M, Almeida V, et al. Pharmaceutics. 2021;13(10):1539. **3.** Fouéré S, Adjadj L, Pawin H. J Eur Acad Dermatol Venereol. 2005;19(S3):2–6. **4.** Berg M, Svensson Å, Faergemann J. Adv Ther. 2013;30(5):503–16. **5.** Ovixan® (1 mg/g cream mometasone furoate) PL 31605 / 0001 Public Assessment Report National Procedure, 2025. **6.** Logamorthy R, Karthikeyan K. Indian J Dermatol Venereol Leprol. 2024;0:1–3. **7.** Broberg A, Åström A. Sensory characterization of skin cream: final report. Göteborg: SIK – The Swedish Institute for Food and Biotechnology; 2011. Report No.: PX10049. **8.** Ovixan® SmPC **9.** Corticosteroids – topical (skin), nose, and eyes. NICE Clin Knowl Summ. 2025 [cited 2025 Dec 1]. Available from: <https://cks.nice.org.uk/topics/corticosteroids-topical-skinnoseeyes/>